Improving testing for hepatitis B before treatment with rituximab. - Wikidata - awgldk - TriplyDB

Improving testing for hepatitis B before treatment with rituximab.

Improving testing for hepatitis B before treatment with rituximab.

http://www.wikidata.org/entity/Q37229995

about

Ocrelizumab and Other CD20(+) B-Cell-Depleting Therapies in Multiple Sclerosis.Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.Human herpes virus-6 encephalitis causing severe anterograde amnesia associated with rituximab, azathioprine and prednisolone combination therapy for dermatomyositis.Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network.

P2860

Q39427711-7BE492A5-F339-489B-B3FA-A4A1C2318199 Q40045559-F8119B7B-67B9-4467-AC49-307FF285D586 Q40324412-09BD9FC9-EE99-4945-8F2B-31F5939073F6 Q45324215-067E7BB2-8CF2-413E-8FCF-3B6952EBD1B2

P2860

Improving testing for hepatitis B before treatment with rituximab.

http://www.wikidata.org/entity/Q37229995

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Improving testing for hepatitis B before treatment with rituximab.

@en

Improving testing for hepatitis B before treatment with rituximab.

@nl

type

label

Improving testing for hepatitis B before treatment with rituximab.

@en

Improving testing for hepatitis B before treatment with rituximab.

@nl

prefLabel

Improving testing for hepatitis B before treatment with rituximab.

@en

Improving testing for hepatitis B before treatment with rituximab.

@nl

P1433

Q37229995-28CA3719-FEA1-42CA-81D2-058E510F27FB

P1476

Q37229995-231F62EE-C40F-4352-A32A-B317C9F9A89D

P2093

Q37229995-11E79B87-B6F4-4F6A-96DC-9E6DC610E105

Q37229995-17CC89B0-1A32-4290-82D9-AD839B734C01

Q37229995-356297E5-7FE2-432C-AD85-49AF3AE54BFF

Q37229995-93306746-D5F5-4F26-8C96-D7725482B7F2

Q37229995-D482E955-962A-4191-BB0A-F3823BC6DD87

Q37229995-E7B7C0BC-5C6A-4A69-8DC8-A70FC39547F0

Q37229995-FEEF1C85-7EF4-43A9-AE0F-15B425B0CC4B

P2860

Q37229995-0FD604E8-B4B8-4D90-BEC8-71D71D17EB9B

Q37229995-120C26C6-34F1-4C0F-A221-E9E244729256

Q37229995-1B83EBFC-F1CC-4DEC-BE69-0ABD0535C1C8

Q37229995-28872C9E-BE5A-4714-B10E-B6B52F977DAD

Q37229995-29C2F41F-891C-400A-A66D-F51D7481F0DF

Q37229995-33E8D1B5-0D13-446A-B2F2-9908BA89782A

Q37229995-34D62536-D6EC-4471-83F8-7AF9FA3CC6FA

Q37229995-3B0EE15F-8BDD-4A1B-8398-9F11876F3334

Q37229995-41D2B840-03D6-4040-918D-B28726E4B184

Q37229995-427AB8FE-351B-4F2C-B1FE-31E7F605AC34

P304

Q37229995-7C9872FE-442D-414C-BA53-14F17AAB5AD3

P31

Q37229995-0A2FE534-A5E4-4B6D-9E1A-4ABE95109171

P356

Q37229995-9BDF743B-3D54-411C-8EF0-13FDA7D093F9

P433

Q37229995-51D3B136-D8CA-436E-97B8-089D62072487

P478

Q37229995-26052121-CD94-485F-8F60-0C560018578E

P50

Q37229995-F6B4B33F-9A79-400F-B039-68D602A4473F

P577

Q37229995-93E444C3-6537-48A9-AF3C-8D3C65F2023F

P698

Q37229995-7630B53D-AD19-481D-B8B6-EA6F8323A93A

P932

Q37229995-33B299DF-1C0E-43A8-AA70-08EB34FD7FA2

P356

MEG.0000000000000689

P1433

European Journal of Gastroenterology and Hepatology

P1476

Improving testing for hepatitis B before treatment with rituximab.

@en

P2093

Jayne Harwood

http://www.w3.org/2001/XMLSchema#string

Jessica K Dyson

http://www.w3.org/2001/XMLSchema#string

Laura Jopson

http://www.w3.org/2001/XMLSchema#string

Manoj Valappil

http://www.w3.org/2001/XMLSchema#string

Matthew Lowery

http://www.w3.org/2001/XMLSchema#string

Sarah Ng

http://www.w3.org/2001/XMLSchema#string

Sheila Waugh

http://www.w3.org/2001/XMLSchema#string

P2860

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura.

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy

Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.

The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system

Low level of hepatitis B virus screening among patients receiving chemotherapy

Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.

A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative.

P304

1172-1178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MEG.0000000000000689

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Stuart McPherson

P577

2016-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27388147

http://www.w3.org/2001/XMLSchema#string

P932

5010281

http://www.w3.org/2001/XMLSchema#string